Data Sheet 2_FOXA2/miR-148a-3p/SMURF2 signaling feed-forward loop alleviates spinal cord ischemia-reperfusion injury-induced neuropathic pain by modulating microglia polarization i... by Xiaotong Hao (20650807)

“…</p>Results<p>SCIRI significantly reduced mechanical and thermal pain thresholds in rats and promoted microglial polarization, with a concomitant decrease in SIRT1 expression and an increase in SMURF2 expression in microglial cells. …”

Impact of Oral Semaglutide on Kidney Outcomes in People with Type 2 Diabetes: Results from the SOUL Randomized Trial by Johannes F. E. Mann (22017555)

“…</p><p dir="ltr">CONCLUSIONS</p><p dir="ltr">In people with T2D and ASCVD and/or CKD but with overall mostly preserved eGFR, orally administered semaglutide, compared to placebo, did not significantly reduce adverse kidney outcomes but did slow the decline in eGFR.…”

Factor associated with neonatal mortality. by Sujan Kumar Naha (20577028)

“…</p><p>Conclusion</p><p>Administering a minimum of one maternal tetanus dose significantly lowers the risk of neonatal mortality. …”

Logic model based on ERIC-CFIR. by Gadapani Barsha Pathak (20700684)

“…If successful, this model can significantly improve stillbirth prevention in low-resource settings.…”

ELISA kit information. by Shuailin Li (11907158)

“…<i>PTGFR</i> and <i>JNK</i> mRNA levels, MMP9 and ADH7 protein levels increased significantly in AN-LSCs after 0.313 μg/mL travoprost treatment (p≤0.039), while NF-κB and ADH7 protein levels decreased significantly in LSCs using 0.313 μg/mL travoprost (p=0.039; p<0.001).…”

Included studies basic characteristics. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

Forest plot for FVC. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

DataSheet1_Effects of Qingjin Huatan decoction on pulmonary function and inflammatory mediators in acute exacerbations of chronic obstructive pulmonary disease: a systematic review... by Xuqin Du (8803772)

“…Compared to conventional treatment, QHD significantly improved pulmonary function, with increases in FEV1 (MD = 0.30, 95% CI: 0.26 to 0.34, p = 0.000), FVC (MD = 0.34, 95% CI: 0.27 to 0.41, p = 0.000), FEV1/FVC (MD = 6.07, 95% CI: 5.55 to 6.58, p = 0.000), and PaO₂ (MD = 7.20, 95% CI: 4.94 to 9.47, p = 0.000), and a decrease in PaCO₂ (MD = −5.37, 95% CI: 7.99 to −2.74, p = 0.000). …”

DataSheet2_Effects of Qingjin Huatan decoction on pulmonary function and inflammatory mediators in acute exacerbations of chronic obstructive pulmonary disease: a systematic review... by Xuqin Du (8803772)

“…Compared to conventional treatment, QHD significantly improved pulmonary function, with increases in FEV1 (MD = 0.30, 95% CI: 0.26 to 0.34, p = 0.000), FVC (MD = 0.34, 95% CI: 0.27 to 0.41, p = 0.000), FEV1/FVC (MD = 6.07, 95% CI: 5.55 to 6.58, p = 0.000), and PaO₂ (MD = 7.20, 95% CI: 4.94 to 9.47, p = 0.000), and a decrease in PaCO₂ (MD = −5.37, 95% CI: 7.99 to −2.74, p = 0.000). …”

All data extracted. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

Table1_Effects of Qingjin Huatan decoction on pulmonary function and inflammatory mediators in acute exacerbations of chronic obstructive pulmonary disease: a systematic review and... by Xuqin Du (8803772)

“…Compared to conventional treatment, QHD significantly improved pulmonary function, with increases in FEV1 (MD = 0.30, 95% CI: 0.26 to 0.34, p = 0.000), FVC (MD = 0.34, 95% CI: 0.27 to 0.41, p = 0.000), FEV1/FVC (MD = 6.07, 95% CI: 5.55 to 6.58, p = 0.000), and PaO₂ (MD = 7.20, 95% CI: 4.94 to 9.47, p = 0.000), and a decrease in PaCO₂ (MD = −5.37, 95% CI: 7.99 to −2.74, p = 0.000). …”

Forest plot for TNF- by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

Cilia disassembly proceeds at a faster rate in CCDC66-depleted cells, which is regulated by the AurkA-HDAC6 axis and rescued by microtubule stabilization. by Jovana Deretic (13113617)

“…Drug treatments decrease ciliary lengths with varying degree across replicates. …”

Demographical features of the sample. by Aymee Lobato Brito (19812790)

“…</p><p>Results</p><p>The evaluated parameters showed significantly different values between the groups, where the Leprosy group exhibited significantly higher values compared to the control group, both in the OE and CE conditions for all four parameters. …”

The impact of excessive DNA amounts used for bisulfite conversion on the amplification efficiency and the methylation level of <i>LINE-1</i> and <i>Alu</i>. by Trang Thi Quynh Tran (20485595)

“…A serial dilution of human methylated DNA amounts, corresponding to 500 ng, 50 ng, 5 ng, 1 ng and 0.5 ng was treated by bisulfite. The ΔCT values significantly differ at input amounts from 500 ng to 0.5 ng. …”

Correlation description. by Aymee Lobato Brito (19812790)

“…</p><p>Results</p><p>The evaluated parameters showed significantly different values between the groups, where the Leprosy group exhibited significantly higher values compared to the control group, both in the OE and CE conditions for all four parameters. …”

Kinetics of differential gene expression after rapid degradation of endogenous OGT in MEFs. by Sara Formichetti (20536052)

“…Note that <i>OsTIR1</i> is also significantly downregulated after auxin addition, suggesting that an unknown mechanism counteracts the degron system upon auxin treatment. …”

Image 4_Low miR-936-mediated upregulation of Pim-3 drives sorafenib resistance in liver cancer through ferroptosis inhibition by activating the ANKRD18A/Src/NRF2 pathway.jpeg by Xiao Li (107004)

“…MiR-936 overexpression and GV102-Pim-3-shRNA significantly attenuated the activity of the ANKRD18A/Src/NRF2 pathway to decrease the expression of Ankyrin repeat domain-containing protein 18A (ANKRD18A), Src, and Nuclear factor (erythroid-derived 2)-like 2 (NRF2), especially decreasing NRF2 nuclear retention and transcriptional activity. …”

Table 1_Variations in vitamin D status among Chinese children aged 1–6 years during the COVID-19 pandemic.xlsx by Yongfeng Qiao (3354326)

“…The average of 25(OH)D concentration were 38.2 ± 9.8 ng/ml, significantly varying by age and season. 25(OH)D concentrations decreased with age, from 42.3 ± 8.8 ng/ml at 1-year-olds to 37.4 ± 8.2 ng/ml at 2-year-olds, and further to 30.2 ± 8.1 ng/ml at 3 to 6-year-olds. …”

Image 2_Low miR-936-mediated upregulation of Pim-3 drives sorafenib resistance in liver cancer through ferroptosis inhibition by activating the ANKRD18A/Src/NRF2 pathway.jpeg by Xiao Li (107004)

“…MiR-936 overexpression and GV102-Pim-3-shRNA significantly attenuated the activity of the ANKRD18A/Src/NRF2 pathway to decrease the expression of Ankyrin repeat domain-containing protein 18A (ANKRD18A), Src, and Nuclear factor (erythroid-derived 2)-like 2 (NRF2), especially decreasing NRF2 nuclear retention and transcriptional activity. …”